BNP PARIBAS ASSET MANAGEMENT Holding S.A. Trims Position in Moderna, Inc. $MRNA

BNP PARIBAS ASSET MANAGEMENT Holding S.A. decreased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 70.5% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 27,703 shares of the company’s stock after selling 66,213 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Moderna were worth $712,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Norges Bank acquired a new position in shares of Moderna in the second quarter valued at approximately $94,910,000. Federated Hermes Inc. raised its position in Moderna by 364.5% during the 2nd quarter. Federated Hermes Inc. now owns 2,869,271 shares of the company’s stock worth $79,163,000 after buying an additional 2,251,497 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Moderna by 19.1% in the 2nd quarter. Geode Capital Management LLC now owns 8,877,280 shares of the company’s stock worth $244,458,000 after acquiring an additional 1,420,690 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Moderna by 3.2% in the second quarter. Vanguard Group Inc. now owns 41,708,705 shares of the company’s stock valued at $1,150,743,000 after acquiring an additional 1,312,192 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Moderna by 20.7% in the second quarter. Invesco Ltd. now owns 7,101,032 shares of the company’s stock valued at $195,917,000 after acquiring an additional 1,217,408 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $49.87 on Friday. The firm has a market capitalization of $19.49 billion, a price-to-earnings ratio of -6.86 and a beta of 1.32. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.29 and a quick ratio of 3.22. The business’s 50 day simple moving average is $39.02 and its 200-day simple moving average is $30.44. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $55.20.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Friday, February 13th. The company reported ($2.11) earnings per share for the quarter, beating the consensus estimate of ($2.79) by $0.68. The firm had revenue of $678.00 million during the quarter, compared to the consensus estimate of $611.14 million. Moderna had a negative return on equity of 30.15% and a negative net margin of 145.16%.Moderna’s quarterly revenue was down 33.2% on a year-over-year basis. During the same period last year, the business posted ($2.91) EPS. As a group, equities analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. BMO Capital Markets upgraded shares of Moderna from a “market perform” rating to a “buy” rating in a research report on Monday, January 12th. UBS Group reissued a “neutral” rating and set a $36.00 target price on shares of Moderna in a research note on Monday. Sanford C. Bernstein restated a “market perform” rating and issued a $45.00 price target on shares of Moderna in a research note on Tuesday. Citigroup reaffirmed a “neutral” rating on shares of Moderna in a report on Monday. Finally, Piper Sandler reiterated an “overweight” rating on shares of Moderna in a research report on Monday, December 1st. Two investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and five have given a Sell rating to the stock. According to data from MarketBeat.com, Moderna presently has a consensus rating of “Reduce” and an average target price of $31.47.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA will review Moderna’s mRNA flu vaccine application after an initial refusal-to-file, with regulators now targeting a decision by Aug. 5, 2026 — a reversal that boosts the commercial outlook for a new recurring vaccine market and spurred an earlier jump in the stock. Moderna Stock Jumps After FDA Reverses Course on Flu Shot
• Positive Sentiment: Goldman Sachs analyst flagged upside for MRNA, an institutional vote of confidence that can support sentiment and buying interest. Moderna (NASDAQ:MRNA) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says
• Neutral Sentiment: Moderna will present at TD Cowen and Barclays healthcare conferences in March — routine investor access that may provide more management detail but is unlikely by itself to move the stock dramatically. Moderna to Present at Upcoming Conferences in March 2026
• Negative Sentiment: BioNTech sued Moderna in Delaware federal court alleging Moderna’s mNexspike infringes a patent tied to BioNTech/Pfizer’s Comirnaty—new litigation increases legal risk, potential damages or injunctions, and heightens competitive/legal uncertainty for Moderna’s COVID-19/respiratory vaccine portfolio. BioNTech sues Moderna for patent infringement over COVID-19 shots
• Negative Sentiment: A court recently rejected two of Moderna’s defenses in its patent dispute with Arbutus, representing another legal setback that could increase exposure and costs from long-running mRNA technology litigation. Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus

Insider Buying and Selling at Moderna

In other news, Director Noubar Afeyan sold 23,853 shares of Moderna stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $29.48, for a total transaction of $703,186.44. Following the completion of the transaction, the director owned 3,924 shares of the company’s stock, valued at $115,679.52. The trade was a 85.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 10.90% of the stock is currently owned by corporate insiders.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.